Decoy Therapeutics (DCOY) Non-Current Debt (2025 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Non-Current Debt of $140000.0 for Q1 2026, little changed quarter-over-quarter from $140000.0 in Q4 2025.
Decoy Therapeutics (DCOY) Non-Current Debt (2025 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Non-Current Debt for 2 consecutive years, with $140000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt changed N/A year-over-year to $140000.0; the TTM figure through Mar 2026 stood at $140000.0 (changed N/A YoY), while the FY2025 annual figure was $140000.0, changed N/A from the prior year.
- Non-Current Debt held at $140000.0 in Q1 2026 per DCOY's latest filing, from $140000.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $140000.0 in Q4 2025 and bottomed at $140000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | 140,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 140,000.00 |
| Mar 31, 2026 | 140,000.00 |
| Dec 31, 2025 | 140,000.00 |